Anavex Life Sciences
|This article is an orphan, as no other articles link to it. Please introduce links to this page from ; try the Find links tool for suggestions. (February 2009)|
|Public OTCQB: AVXL|
|Headquarters||New York, New York, USA|
Christopher U. Missling, MS, PhD, MBA, President and CEO|
Tom Skarpelos, Director
Michael Gold, MD, Scientific Advisory Board
Ottavio Arancio, MD, PhD, Scientific Advisory Board
Tangui Nicolas Maurice, Ph.D., Scientific Advisory Board
Paul Aisen, MD, Scientific Advisory Board – Clinical Expert
Jeffrey Cummings, MD, Scientific Advisory Board – Clinical Expert
Anavex Life Sciences Corp. is a pharmaceutical company that develops drug candidates.
ANAVEX 2-73 has been shown to provide protection from oxidative stress, which damages and destroys neurons and is believed to be a primary cause of Alzheimer's disease. Research in recent years indicates that oxidative stress is a precursor to amyloid-beta plaques and tau (see also Neuro-Fibrillary Tangles), and could be a novel and appropriate therapeutic target.